ibrutinib

AbbVie pens Imbruvica pact to support pivotal Oncternal trial

AbbVie has helped Oncternal move a step closer to the start of a phase 3 trial by agreeing to supply its BTK inhibitor ibrutinib for use in the study.

Nick Paul Taylor Jul 15, 2022 9:55am

Kymera targets protein degradation to treat lymphoma

Jun 19, 2019 10:31am

New discoveries in Lyme disease and cancer—News of Note

Feb 5, 2018 5:00pm

Redx sells cancer drug to Loxo to escape debt crisis

Jul 31, 2017 8:29am